Physician profile
John P Cook
NPI 1578030813
$5,690.91
in general payments reported to CMS, 2019-2025
27 companies · $1,934 in 2025
The $1,934 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $499 · 2023: $1,987 · 2024: $691 · 2025: $1,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,612.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $772.50 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $664.53 | 2021-2023 | Austedo, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.12 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $464.83 | 2023-2025 | Spravato, Invega |
| Axsome Therapeutics, INC. | $296.94 | 2023-2024 | Auvelity |
| Abbvie INC. | $242.37 | 2021-2024 | |
| Gilead Sciences, INC. | $221.82 | 2023-2025 | Livdelzi, Epclusa |
| Alexion Pharmaceuticals, INC. | $219.93 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $219.92 | 2023-2025 | Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $214.30 | 2024-2025 | Cobenfy |
| Abbott Laboratories | $145.89 | 2025 | Proclaim |
| Abiomed | $125.69 | 2025 | |
| Harmony Biosciences LLC | $124.98 | 2023 | Wakix |
| Kyowa Kirin, INC. | $123.16 | 2024 | |
| Corcept Therapeutics | $122.98 | 2025 | Korlym |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $119.02 | 2023 | |
| Inspire Medical Systems, INC. | $118.62 | 2023 | Inspire |
| Livanova USA, INC. | $111.73 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Xeris Pharmaceuticals, INC. | $106.94 | 2025 | Recorlev |
| Edwards Lifesciences Corporation | $100.92 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Glaxosmithkline, LLC. | $98.88 | 2022 | |
| Idorsia Pharmaceuticals US INC | $96.19 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $96.19 | 2025 | |
| Mylan Specialty L.P. | $93.53 | 2023 | Yupelri |
| Eli Lilly and Company | $92.53 | 2023 | |
| Eisai INC. | $84.38 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $31.02 | 2023 | Iovera, Zilretta, Exparel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.